[go: up one dir, main page]

WO2006028523A3 - Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors - Google Patents

Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors Download PDF

Info

Publication number
WO2006028523A3
WO2006028523A3 PCT/US2005/014747 US2005014747W WO2006028523A3 WO 2006028523 A3 WO2006028523 A3 WO 2006028523A3 US 2005014747 W US2005014747 W US 2005014747W WO 2006028523 A3 WO2006028523 A3 WO 2006028523A3
Authority
WO
WIPO (PCT)
Prior art keywords
metalloprotein
hydroxypyridinethione
thiopyrone
hydroxypyridinone
pyrone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/014747
Other languages
French (fr)
Other versions
WO2006028523A2 (en
Inventor
David T Puerta
Seth M Cohen
Jana A Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/009277 external-priority patent/WO2005110399A2/en
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to US11/568,505 priority Critical patent/US7705164B2/en
Priority to EP05818191A priority patent/EP1755586A2/en
Publication of WO2006028523A2 publication Critical patent/WO2006028523A2/en
Publication of WO2006028523A3 publication Critical patent/WO2006028523A3/en
Anticipated expiration legal-status Critical
Priority to US11/554,475 priority patent/US7579486B2/en
Priority to US12/503,190 priority patent/US7786316B2/en
Priority to US12/722,623 priority patent/US8008510B2/en
Priority to US13/209,577 priority patent/US8318945B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.
PCT/US2005/014747 2004-04-29 2005-04-28 Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors Ceased WO2006028523A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US11/568,505 US7705164B2 (en) 2004-04-29 2005-04-28 Metalloprotein inhibitors
EP05818191A EP1755586A2 (en) 2004-04-29 2005-04-28 Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors
US11/554,475 US7579486B2 (en) 2004-04-29 2006-10-30 Metalloprotein inhibitors
US12/503,190 US7786316B2 (en) 2004-04-29 2009-07-15 Metalloprotein inhibitors
US12/722,623 US8008510B2 (en) 2004-04-29 2010-03-12 Metalloprotein inhibitors
US13/209,577 US8318945B2 (en) 2004-04-29 2011-08-15 Metalloprotein inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US56688204P 2004-04-29 2004-04-29
US60/566,882 2004-04-29
US57644404P 2004-06-03 2004-06-03
US60/576,444 2004-06-03
PCT/US2005/009277 WO2005110399A2 (en) 2004-04-29 2005-03-21 Zinc-binding groups for metalloprotein inhibitors
USPCT/US2005/009277 2005-03-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/009277 Continuation-In-Part WO2005110399A2 (en) 2004-04-29 2005-03-21 Zinc-binding groups for metalloprotein inhibitors

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US11/568,505 A-371-Of-International US7705164B2 (en) 2004-04-29 2005-04-28 Metalloprotein inhibitors
US11/554,475 Continuation-In-Part US7579486B2 (en) 2004-04-29 2006-10-30 Metalloprotein inhibitors
US11/554,478 Continuation-In-Part US10445703B1 (en) 2006-10-30 2006-10-30 Early enough reminders
US12/722,623 Division US8008510B2 (en) 2004-04-29 2010-03-12 Metalloprotein inhibitors
US13/209,577 Division US8318945B2 (en) 2004-04-29 2011-08-15 Metalloprotein inhibitors

Publications (2)

Publication Number Publication Date
WO2006028523A2 WO2006028523A2 (en) 2006-03-16
WO2006028523A3 true WO2006028523A3 (en) 2006-06-01

Family

ID=35840413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014747 Ceased WO2006028523A2 (en) 2004-04-29 2005-04-28 Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors

Country Status (2)

Country Link
EP (1) EP1755586A2 (en)
WO (1) WO2006028523A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579486B2 (en) 2004-04-29 2009-08-25 Regents Of The University Of California, San Diego Metalloprotein inhibitors
US12479792B2 (en) 2016-09-29 2025-11-25 The Regents Of The University Of California Compositions of chelating molecules

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002109A2 (en) * 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
CN101547908A (en) * 2006-10-05 2009-09-30 詹森药业有限公司 Heterocyclic derived metalloprotease inhibitors
EP2337544A2 (en) * 2007-04-30 2011-06-29 Living Proof, Inc. Use of matrix metalloproteinase inhibitors in skin care
CA2733931A1 (en) * 2008-08-15 2010-02-18 Burnham Institute For Medical Research Composition and methods for the design and development of metallo-enzyme inhibitors
US8889638B2 (en) 2010-06-22 2014-11-18 The Regents Of The University Of California Stimulus-triggered prodrugs
CN102531964B (en) * 2011-10-10 2014-06-11 华东理工大学 Dicarboxylic acid derivatives with anti-tumor effect and preparation method thereof
PH12019501848A1 (en) 2012-12-21 2020-03-02 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
NO2865735T3 (en) 2013-07-12 2018-07-21
WO2015006731A1 (en) 2013-07-12 2015-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2717902T3 (en) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (en) 2014-06-20 2021-11-01 美商基利科學股份有限公司 Synthesis of polycyclic-carbamoylpyridone compounds
WO2017083434A1 (en) 2015-11-09 2017-05-18 Forge Therapeutics, Inc. Pyrone based compounds for treating bacterial infections
US10414735B2 (en) 2015-11-09 2019-09-17 Forge Therapeutics, Inc. Substituted hydroxypyrimidinones for treating bacterial infections
US10982136B2 (en) 2016-02-26 2021-04-20 The Regents Of The University Of California Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters
EP4529966A3 (en) 2016-08-29 2025-06-18 Fred Hutchinson Cancer Center Chelating platform for delivery of radionuclides
US11684614B2 (en) 2016-09-06 2023-06-27 The Regents Of The University Of California Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
CA3038723A1 (en) 2016-09-29 2018-05-31 The Regents Of The University Of California Separation of metal ions by liquid-liquid extraction
US11021471B2 (en) 2017-05-10 2021-06-01 Forge Therapeutics, Inc. Antibacterial compounds
JP7495395B2 (en) 2018-09-20 2024-06-04 ブラックスミス メディシンズ，インク． Antibacterial Compounds
CN111662228B (en) * 2019-03-07 2023-07-28 中国医学科学院药物研究所 Pyridone acyl biarylamine compounds and uses thereof
WO2021195260A1 (en) 2020-03-25 2021-09-30 Forge Therapeutics, Inc. Lpxc inhibitor and methods of making
AU2022357226A1 (en) 2021-09-28 2024-05-02 Blacksmith Medicines, Inc. Lpxc inhibitors and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585780A (en) * 1983-03-24 1986-04-29 National Research Development Corp. Pharmaceutical compositions
US5981496A (en) * 1997-09-19 1999-11-09 Millennium Pharmaceutical, Inc. α-pyrones for treating α-pyrone responsive states
EP1006112A1 (en) * 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers
US6552073B1 (en) * 2002-03-01 2003-04-22 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases
US20040063673A1 (en) * 2002-08-13 2004-04-01 Johnson Adam Richard Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
WO2004110442A1 (en) * 2003-06-09 2004-12-23 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Pyridine n-oxides as antiviral agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585780A (en) * 1983-03-24 1986-04-29 National Research Development Corp. Pharmaceutical compositions
US5981496A (en) * 1997-09-19 1999-11-09 Millennium Pharmaceutical, Inc. α-pyrones for treating α-pyrone responsive states
EP1006112A1 (en) * 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers
US6552073B1 (en) * 2002-03-01 2003-04-22 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases
US20040063673A1 (en) * 2002-08-13 2004-04-01 Johnson Adam Richard Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
WO2004110442A1 (en) * 2003-06-09 2004-12-23 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Pyridine n-oxides as antiviral agents

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ATKINSON, J.G. ET AL.: "Kojic amine a novel gamma-aminobutyric acid analogue", J OF MEDICINAL CHEMISTRY, vol. 22, no. 1, 1979, pages 99 - 106, XP002364809 *
DILSIZ AYTEMIR, M. ET AL.: "Synthesis and evaluation of antimicrobial activity of new 3-hydroxy-6-methyl-4-oxo-4H-pyran-2-carboxamide derivatives", TURKISH JOURNAL OF CHEMISTRY, vol. 27, no. 6, 2003, pages 757 - 764, XP009060662 *
LIM, S.: "Competitive inhibition of tyrosinase by 5-hydroxy-2-phenylalanylaminomethyl-4-pyron", YAKHAK HOECHI, vol. 44, no. 3, 2000, pages 279 - 282, XP009060670 *
PUERTA, D.T. EGT AL.: "Potent, selective pyrone-based inhibitors of stromelysin-1", J AM CHEM SOC, vol. 127, no. 41, 2005, pages 14148 - 14149, XP002364810 *
STORR, T. ET AL.: "Vanadyl-thiazolidinedione combination agents for diabetes therapy", BIOCONJIGATE CHEM, vol. 14, no. 1, 2003, pages 212 - 221, XP002364808 *
WOODS, L.L.: "Mannich bases from kojic acid and aryl amines", J OF THE AMERICAN CHEMISTRY SOCIETY, vol. 68, 1946, pages 2744 - 2745, XP009060665 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579486B2 (en) 2004-04-29 2009-08-25 Regents Of The University Of California, San Diego Metalloprotein inhibitors
US12479792B2 (en) 2016-09-29 2025-11-25 The Regents Of The University Of California Compositions of chelating molecules

Also Published As

Publication number Publication date
WO2006028523A2 (en) 2006-03-16
EP1755586A2 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
WO2006028523A3 (en) Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors
WO2005110399A3 (en) Zinc-binding groups for metalloprotein inhibitors
WO2005072412A3 (en) Anti-viral therapeutics
WO2008076427A3 (en) Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
WO2007112052A3 (en) Formulations and methods for vascular permeability-related diseases or conditions
WO2009126863A3 (en) Pyridyl inhibitors of hedgehog signalling
NO20081454L (en) Met kinase inhibitors
WO2009154300A3 (en) Heterocyclic compound and use thereof
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
WO2006079021A3 (en) Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
NO20070247L (en) Amino-5,5-diphenylimidazolone derivatives for inhibition of beta-secretase
WO2006113942A3 (en) Method of inhibiting cathepsin activity
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
NO20081846L (en) Biphenyl derivatives and their use in the treatment of hepatitis C
WO2008024892A3 (en) Cyclic 11-beta hydroxysteroid dehydrogenase type i inhibitors
WO2005049084A3 (en) Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
TW200716116A (en) Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008019395A3 (en) Compounds for improving learning and memory
WO2007109459A3 (en) Pyridines and pyridine n-oxides as modulators of thrombin
WO2006135604A3 (en) Inhibitors of checkpoint kinases
NO20071222L (en) Benzamide.
WO2009098458A3 (en) Difluorobiphenylamide derivatives for the treatment of ocular hypertension
WO2004060264A3 (en) Metastin derivatives and their use
ATE529531T1 (en) GM3 SYNTHASE AS A THERAPEUTIC TARGET IN MICROVASCULAR COMPLICATIONS OF DIABETES
WO2007115805A3 (en) Aurora kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11554475

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005818191

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005818191

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11554475

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11568505

Country of ref document: US